Skip to main content

Specialized Biotech ETF Rallies on MacroGenics Positive Trial Results

A biotechnology sector-specific exchange traded fund specialized in tracking immunotherapy drugmakers bucked the broader market trends and surged Wednesday after MacroGenics (NasdaqGS: MGNX) announced upbeat breast cancer trail results. The Loncar Cancer Immunotheraphy ETF (NasdaqGM: CNCR), which...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.